CLSA has released a research report stating that Shanghai Pharmaceuticals (02607) reported revenue of RMB 283.6 billion for the 2025 fiscal year, a 3% year-on-year increase, and a net profit of RMB 5.73 billion, up 25.7% year-on-year. Both figures were largely in line with market expectations. Traditional Chinese medicine has consistently been the core driver of the company's manufacturing operations, and the company will continue to prioritize the development of innovative drug R&D to fuel growth. The firm has raised its target price from HK$14.2 to HK$15.2, maintaining an "Outperform" rating.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments